Biogen says it expects revenue to fall in 2026 as its multiple sclerosis therapies continue to struggle.
Investor's Business Daily on MSN
How one drug heavy-lifted Biogen's fourth-quarter beat
Biogen topped fourth-quarter expectations Friday, thanks to far better-than-expected sales of multiple sclerosis treatment ...
Feb 6 (Reuters) - Biogen forecast 2026 profit above Wall Street estimates on Friday, banking on demand for newer medicines ...
VANCOUVER,BC / ACCESS Newswire / September 29, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience company specializing in innovative drug delivery ...
Explore how Epstein-Barr may link to multiple sclerosis, affecting nearly one million people in the United States.
Shares of Sanofi slumped on Monday as the French drugmaker said a U.S. regulatory review of its multiple-sclerosis drug won’t be completed by the end of the year and a trial for a different form of MS ...
Roche Holdings AG (OTC:RHHBY) on Friday announced new 96-week data for fenebrutinib demonstrating that patients with relapsing multiple sclerosis (RMS) maintained no disability progression and low ...
Nearly 80% of US neurologists prescribing drugs for multiple sclerosis (MS) received at least one pharma industry payment, with higher volume prescribers more likely to be beneficiaries, finds a 5 ...
Add Yahoo as a preferred source to see more of our stories on Google. A logo of Sanofi at the company’s booth at the 8th China International Import Expo (CIIE) in Shanghai, China, November 6, ...
Sanofi SAN-0.38%decrease; red down pointing triangle said a U.S. regulatory decision on its tolebrutinib experimental treatment for a type of multiple sclerosis would be delayed again, and that a late ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results